Trials / Completed
CompletedNCT00938639
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults
A Phase II, Single-centre, Randomised, Observer-blind Study to Evaluate the Immunogenicity, Safety and Tolerability of CSL's Monovalent H1N1 Influenza Virus Vaccine in Healthy Adults Aged 18 to < 65 Years.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Seqirus · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL425 | CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume) |
| BIOLOGICAL | CSL425 | CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume) |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2009-09-01
- Completion
- 2010-03-01
- First posted
- 2009-07-14
- Last updated
- 2018-06-28
- Results posted
- 2013-11-21
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00938639. Inclusion in this directory is not an endorsement.